Mesenchymal stem cells-like as a prognostic biomarker in patients diagnosed with acute myeloid leukemia.
1/5 보강
The bone marrow microenvironment influences acute myeloid leukemia (AML) progression.
- p-value P < 0.001
- p-value P = 0.027
- 95% CI 2.53-16.33
- HR 6.43
APA
Castaño-Bonilla T, Láinez-González D, et al. (2025). Mesenchymal stem cells-like as a prognostic biomarker in patients diagnosed with acute myeloid leukemia.. Scientific reports, 15(1), 42680. https://doi.org/10.1038/s41598-025-26852-x
MLA
Castaño-Bonilla T, et al.. "Mesenchymal stem cells-like as a prognostic biomarker in patients diagnosed with acute myeloid leukemia.." Scientific reports, vol. 15, no. 1, 2025, pp. 42680.
PMID
41315789 ↗
Abstract 한글 요약
The bone marrow microenvironment influences acute myeloid leukemia (AML) progression. Mesenchymal stem cell-like (MSC-l) populations may exert tumor-modulating effects, but their prognostic role remains uncertain. We retrospectively analyzed 65 adult AML patients (excluding acute promyelocytic leukemia) treated with intensive chemotherapy between 2017 and 2024 at four Spanish institutions. MSC-l cells were identified in BM aspirates at end of treatment by multiparameter flow cytometry (CD13/CD45/CD34/CD117/CD11b/CD16/CD71/CD64). Patients were stratified using a 0.265%cutoff (MSC-l ≥ 0.265% and MSC-l < 0.265%). Survival was assessed with Kaplan-Meier and Cox regression, adjusting for age and ELN 2017 risk. MSC-l patients had inferior overall survival (OS) (median 0.66 years vs. not reached; P < 0.001) and relapse-free survival (RFS) (median 1.27 years vs. 1.49 years; P = 0.027). These associations persisted across ELN risk groups. Multivariate analysis confirmed MSC-l status as an independent predictor of worse OS (HR = 6.43; 95% CI 2.53-16.33; P < 0.001) and RFS (HR = 4.8; 95% CI 1.71-13.47; P = 0.003). MSC-l levels were lower in patients receiving myeloablative conditioning compared with non-transplanted patients, suggesting transplant intensity may influence MSC dynamics. Higher post-treatment MSC-l proportions are associated with poorer survival, independent of ELN risk and age, supporting their potential as a prognostic biomarker in AML.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.